Evaxion Biotech AS Market Cap ($26.70 Million)
Market Cap & Net Worth: Evaxion Biotech AS (EVAX)
Evaxion Biotech AS market cap. Evaxion Biotech AS (NASDAQ:EVAX) has a market capitalization of $26.70 Million ($26.70 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23977 globally and #5194 in its home market, demonstrating a -3.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evaxion Biotech AS's stock price $2.96 by its total outstanding shares 9021483 (9.02 Million). Also see Evaxion Biotech AS (EVAX) cash flow conversion for how efficiently the company converts equity into cash flow.
Evaxion Biotech AS Market Cap History (2021–2026)
Evaxion Biotech AS market cap history from 2021 to 2026. Data shows change from $398.75 Million to $26.70 Million (-45.71% CAGR). Check EVAX share price today for real-time trading data and today's change.
Index Memberships
Evaxion Biotech AS is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #674 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2235 of 3165 |
Weight: Evaxion Biotech AS's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Evaxion Biotech AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evaxion Biotech AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Evaxion Biotech AS net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.72x
Evaxion Biotech AS's market cap is 5.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $61.89 Million | $73.00K | -$22.12 Million | 847.77x | N/A |
| 2024 | $7.63 Million | $3.34 Million | -$10.57 Million | 2.28x | N/A |
| 2025 | $43.03 Million | $7.53 Million | -$7.71 Million | 5.72x | N/A |
Competitor Companies of EVAX by Market Capitalization
Companies near Evaxion Biotech AS in the global market cap rankings as of November 5, 2026. Also see Evaxion Biotech AS balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Evaxion Biotech AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Evaxion Biotech AS (2021–2026)
Market capitalization of Evaxion Biotech AS from 2021 to today. Between 2021 and today, Evaxion Biotech AS's market cap moved from $398.75 Million to $ 26.70 Million, with a yearly change of -45.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $26.70 Million | -37.95% |
| 2025 | $43.03 Million | +464.23% |
| 2024 | $7.63 Million | -87.68% |
| 2023 | $61.89 Million | -61.35% |
| 2022 | $160.13 Million | -59.84% |
| 2021 | $398.75 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Evaxion Biotech AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.70 Million USD |
| MoneyControl | $26.70 Million USD |
| MarketWatch | $26.70 Million USD |
| marketcap.company | $26.70 Million USD |
| Reuters | $26.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid le… Read more